Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities

Three transactions announced this week cover very different points in the drug development pipeline: AI-driven target discovery, an early clinical-stage multispecific biologic, and the trace-level analytical work behind product release.^1-3 In each case, a company is choosing to get a specialized capability from a partner rather than build it internally.

What Does the Tempus–BMS Agreement Give Oncology Researchers?

Tempus AI announced a multi-year agreement under which Bristol Myers Squibb (BMS) will license de-identified multimodal oncology data through 2031.¹ BMS will use the data to support target discovery, biological and clinical insight identification, and therapeutic development across its oncology portfolio. BMS will also get access to Tempus' Lens Platform, an agentic AI environment connected to dedicated computing infrastructure, where its researchers can train and run their own models. The deal builds on an existing collaboration that applies real-world data to clinical trial design in oncology and neuroscience, and it makes BMS one of Tempus' largest data licensors. The agreement continues a pattern at BMS, which earlier this year said it would expand its in-house AI computing capacity with NVIDIA. For development teams, the open question is whether models trained on real-world data can measurably improve candidate selection before programs reach costly process development and clinical supply manufacturing.

How Is the ZW209 Deal Structured, and Why Does the Molecule Matter?

Zymeworks entered an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T-cell engager targeting DLL3.² Zymeworks will receive $55 million upfront and $40 million when the Phase 1b trial begins. It is also eligible for up to $718 million in milestones, plus tiered royalties ranging from high single digits to the mid-teens. Zymeworks will run the Phase 1a monotherapy trial, which Roche will fund. Roche will then lead global development and commercialization. The transaction is still subject to antitrust review.

ZW209 binds DLL3-expressing tumor cells, engages T cells, and adds CD28 co-stimulation.² The CD28 signal is engaged conditionally so that T cells are not activated where they shouldn't be. The planned study will enroll patients with small cell lung cancer and other DLL3-expressing neuroendocrine tumors.

“ZW209 represents an innovative approach that complements our ongoing efforts to develop new treatment options for people living with lung cancer,” said Boris L. Zaïtra, Head of Corporate Business Development, Roche, in a press release.² “We look forward to collaborating with Zymeworks to fully explore its therapeutic potential.”

What Does Sannova Add to LGM Pharma's Analytical Services?

LGM Pharma acquired Sannova Analytical, a contract laboratory in Somerset, New Jersey.³ The deal adds Good Laboratory Practice (GLP) bioanalysis, including peptide and oligonucleotide testing, to LGM Pharma's cGMP analytical services. It also adds genotoxic and nitrosamine impurity testing, extractables and leachables evaluations, and expanded elemental impurities testing. The laboratory has completed more than 1,500 GLP studies and 3,500 cGMP analytical studies, and its most recent FDA inspection, in 2025, resulted in no action indicated.

“Over the last five years, we've built analytical testing into a standalone business, and the two things our clients keep asking for are bioanalysis and more extensive impurity work,” said Prasad Raje, PhD, CEO, LGM Pharma, in a press release.³ “Sannova gives us both, along with a US-based team that develops and validates its methods at the center of the Northeast pharmaceutical corridor. This acquisition provides additional capabilities, but it also adds capacity for the growing volume of work our clients are bringing to us.”

The demand Raje describes is grounded in regulation.³ The FDA's acceptable intake limits for nitrosamine impurities are set below what routine quality control methods can reliably detect. Recurring problems such as the duloxetine recalls show that this testing burden is not going away.

What Ties These Three Deals Together?

Each deal brings in a specialized capability (data and computing, multispecific engineering, or trace-level analytics) that would be slow or expensive to build internally.^1-3 For development and manufacturing professionals, three practical points follow:

• Earlier decisions: If data-driven candidate selection works as intended, program attrition could shift earlier in development.
• Earlier readiness: Complex modalities like trispecifics will require analytical and process readiness sooner than conventional antibodies do.
• Partner continuity: Analytical testing capacity is consolidating. Sponsors should confirm that qualified methods and laboratory teams stay intact when their testing partners change ownership.

References

1. Tempus AI, Inc. Tempus expands strategic collaboration with Bristol Myers Squibb. News release. Business Wire. October 23, 2026. Accessed October 23, 2026. View source

2. Zymeworks Inc. Zymeworks enters into an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. News release. October 23, 2026. Accessed October 23, 2026. View source

3. LGM Pharma. LGM Pharma acquires Sannova Analytical, expanding cGMP analytical and GLP bioanalytical services. Published October 22, 2026. Accessed October 23, 2026. View source